RASSF1A and ERCC1 Expression Levels Might Be Predictive of Prognosis in Advanced, Recurrent, and Metastatic Squamous Cell Carcinoma of the Head and Neck Treated with Docetaxel and Cisplatin

By  

Oncology Research and Treatment, Vol. 35, Iss. 11, 2012-10 ,pp. : 673-682

Karger

Access to resources Recommend Favorite

Randomized phase III study of 2 cisplatin‐based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: Impact of changing disease epidemiology on contemporary trial design

By  

HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Vol. 37, Iss. 11, 2015-11 ,pp. : 1583-1589

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term results of weekly/daily cisplatin‐based chemoradiation for locally advanced squamous cell carcinoma of the anal canal

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3769-3775

John Wiley & Sons Inc

Access to resources Recommend Favorite

Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck

By Levy Adrian R.   Johnston Karissa M.   Sambrook Jennifer   Donato Bonnie   Penrod John R.   Corral Mitra   Chasen Martin  

Current Medical Research and Opinion, Vol. 27, Iss. 12, 2011-12 ,pp. : 2253-2259

Informa Healthcare

Access to resources Recommend Favorite

Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10‐year update and subset analysis

By  

CANCER, Vol. 121, Iss. 10, 2015-05 ,pp. : 1599-1607

John Wiley & Sons Inc

Access to resources Recommend Favorite